THE TAPE
UTHR · Pharmaceutical Preparations · $25.2B

United Therapeutics Corp

$587.88▼ −0.56%
Last close
Relative strength
70RS
of 99, against every stock▲ +15 on the month
Powering up
Turning
−6.7%
six months against Pharmaceutical Preparations
52-week range
−4.3%
from the high
$455.63$614.23
Setup
vcpplayed out
+13.1%
against the pivot at $519.99
No report date on the calendar.
Growth FLATProof SHOWN
Quarter to Sep 30, revenue +4% on a year ago
11/16 O 592.27 H 595.66 L 578.71 Vol 441.7K
Draw
9-dayabout two weeks21-dayabout a month50-dayabout a quarter200-dayabout a year

All four are in order, fastest above slowest — every timeframe pointing the same way.

RS70
vs pivot+13.06%
Tightening1.12×
Dry-up1.14×
Up/down vol0.04
From high4%
played out7 of 9checks
Powering up
Support and resistance
Support below
$557.63
-5.1% · tested 7× · last 5 sessions ago
Resistance above
None within the last 120 sessions

Prices this stock has turned at three or more times in the last 120 sessions, with how many times. Where buyers and sellers showed up before, not a forecast, an entry or a stop.

The read

The base has run 8.4 weeks and fell 12% from its ceiling at its deepest. The pivot is $519.99, and the stock closed 13.1% above that pivot. Its relative strength rating is 70.

Against its industry
TurningBehind its industry over six months, but ahead over one and three.
One month against its industry
+5.6%
Three months against its industry
+31.1%
Six months against its industry
-6.7%

Read against an equal-weighted index of Pharmaceutical Preparations, which is +10.9% against the S&P 500 over six months Partly aligned.

Also on
Peers
Catalyst roadmap

Nothing dated in the next three months that we can ingest automatically.

How it moves on earnings

On average 5.5% either way across its last 8 reports.

Checking your subscription…

Close before the report day to close after it, so it holds whether the company reported before the open or after the close.

The business
Revenue
$3.2B
+4.1% year on year
Operating margin
41.4%
gross 86.3%
Net margin
38.6%
Free cash flow
$867.2M
3.4% of market cap
Price to sales
7.91×
Price to earnings
20.5×

Twelve months to Sep 30, 2026, the four latest quarters in the company’s SEC filings, with the fiscal fourth quarter worked out from the annual report. Revenue growth is the latest quarter against the same quarter a year earlier.

The latest quarter, read by fixed rules · reported Nov 4
Key takeaway
Profitable and cash generating; the question is growth.
Revenue
$832.5M
+6.3% QoQ · +4.1% YoY
Gross margin
88.1%
+0.8 pts QoQ
Net income
$258.6M
Positive
Free cash flow
$125.8M
Cash generating

What the numbers say

  • Revenue +4.1% year over year, +6.3% on the quarter
  • Gross margin 88.1%, +0.8 points on the quarter
  • Good: Profitable: net income $259M, operating margin 37.0%
  • Good: Cash generating: operating cash flow $306M, free cash flow $126M
  • Good: Share count -4.2% in a year: buying back
  • Good: Net cash $1.19B · cash $1.19B
Revenue by quarter
Free cash flow
Net income
shares -4.2% in a year · net cash $1.2B
Final read
Growth: FLAT · Economic proof: SHOWN
Key question: Can the cash generation hold as growth slows?
The next test is whether the quarter repeats.

From the company’s 10-Q and 10-K filings, by Market Desk’s rules. Every line, the takeaway and the final read are fixed rules on the filed numbers; nothing reads the press release, and none of it enters a screen or a rating. Every recent reporter.

Tracked funds

Held by 2 of 46 tracked funds at the end of Q3 2026.

Last quarter: 1 bought new, 1 trimmed.

Checking your subscription…

From 13F filings, which show long stock only and arrive up to 45 days after the quarter. The broad quant funds are left out.

Flagged by the market sweep
Several insiders soldInsider · 2026-11-14
3 insiders sold $130,826,009
No measurable effect: stocks behave like random ones over the next three sessions (653 cases over 60 nights).
Several insiders soldInsider · 2026-11-13
3 insiders sold $135,596,165
No measurable effect: stocks behave like random ones over the next three sessions (653 cases over 60 nights).
Several insiders soldInsider · 2026-11-11
3 insiders sold $124,383,211
No measurable effect: stocks behave like random ones over the next three sessions (653 cases over 60 nights).
Several insiders soldInsider · 2026-11-10
2 insiders sold $112,858,813
No measurable effect: stocks behave like random ones over the next three sessions (653 cases over 60 nights).
Several insiders soldInsider · 2026-11-07
2 insiders sold $128,267,159
No measurable effect: stocks behave like random ones over the next three sessions (653 cases over 60 nights).
Several insiders soldInsider · 2026-11-06
2 insiders sold $127,913,965
No measurable effect: stocks behave like random ones over the next three sessions (653 cases over 60 nights).
GappedTape · 2026-11-06
-7.0%
After this signal, stocks have lagged random stocks by 0.9% over the next three sessions (18,291 cases over 56 nights). Against their own sector they have lagged by 1.2%.
Reported resultsFiling · 2026-11-05
2.02
No measurable effect: stocks behave like random ones over the next three sessions (2,340 cases over 54 nights).

From a separate overnight market sweep, not from the screens on this site. What it flagged, not what it means. The track record is the sweep's own, measured against random stocks over the last 90 days.

In the news
Insiders
Bought on the open market
0
Sold on the open market
1554
$726,548,663 total

Sold: ROTHBLATT MARTINE A, PATUSKY CHRISTOPHER, MAHON PAUL A, Mesa Nilda, MALCOLM JAN, EDGEMOND JAMES.

Not counted above: 161 filings for awards, option exercises, gifts or shares withheld to pay tax. Those follow a vesting schedule nobody chose the timing of, and counting them as selling is how that number gets misread.

Most recent filings
2026-11-13 ROTHBLATT MARTINE A · Chairperson & CEO, Directoroption exercise9,500$1,118,720
2026-11-13 ROTHBLATT MARTINE A · Chairperson & CEO, Directorsell528$310,156
2026-11-13 ROTHBLATT MARTINE A · Chairperson & CEO, Directorsell493$290,183
2026-11-13 ROTHBLATT MARTINE A · Chairperson & CEO, Directorsell603$355,647
2026-11-13 ROTHBLATT MARTINE A · Chairperson & CEO, Directorsell1,657$978,702
2026-11-13 ROTHBLATT MARTINE A · Chairperson & CEO, Directorsell2,181$1,290,198
2026-11-13 ROTHBLATT MARTINE A · Chairperson & CEO, Directorsell518$306,973
2026-11-13 ROTHBLATT MARTINE A · Chairperson & CEO, Directorsell245$145,483

From SEC Form 4, filed within two business days of the trade. What was filed, not what it means.

What lines up

7 of 9 published checks currently line up. This is a count, not a probability — nothing on this site measures how often a setup works.

Relative strength of 80 or better
Above its 50-day line
Above its 200-day line
Averages fully stacked
Within 5% of its pivot
Range tightening through the base
Volume drying up through the base
More up-volume than down-volume
Within 15% of its 52-week high
What analysts expect
Strong buy3
Buy9
Hold2
Sell1
Strong sell0

These are analysts’ estimates, not ours, and not a projection this site endorses. They are published here because what the sell side expects is itself a fact about the market.

Checking your subscription…

Gamma concentration

No option open interest for this company. Most listed names have no options at all, and we only read chains for names carrying a dated event, so this is a normal reading rather than a fault.

X-ray

The most recent of 2 completed bases.

Checking your subscription…

A screening and market-analytics tool. Not investment advice. We are not a registered investment adviser. A stock on a screen matches a shape; that is not a prediction. Prices are end-of-day, not live.

What that means, in full
United Therapeutics Corp (UTHR) — The Tape